(1R,3R)-1,3-dimethylcyclopentane-1,3-dicarboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1R,3R)-1,3-dimethylcyclopentane-1,3-dicarboxylic acid
• 化学式: C₉H₁₄O₄
• 分子量: 186.2
• InChiKey: FOJXFBYPGKKIJQ-RKDXNWHRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Benzamide imidazopyrazine Btk inhibitors
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US10087188B2

  公开（公告）日：2018-10-02

  The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

  本发明提供了根据式（I）的布鲁顿酪氨酸激酶（Btk）抑制剂化合物或其药学上可接受的盐，或包含这些化合物的药物组合物及其在治疗中的用途。特别是，本发明涉及式（I）的 Btk 抑制剂化合物在治疗 Btk 介导的疾病中的用途。
• Tertiary alcohol imidazopyrazine BTK inhibitors
  申请人：Liu Jian

  公开号：US10208047B2

  公开（公告）日：2019-02-19

  The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, Formula I or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.

  本发明提供了根据式I的布鲁顿酪氨酸激酶（Btk）抑制剂化合物，或其药学上可接受的盐，式I或包含这些化合物的药物组合物，以及它们在治疗中的用途。特别是，本发明涉及式 I 的 Btk 抑制剂化合物在治疗 Btk 介导的疾病中的用途。
• TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3240546A1

  公开（公告）日：2017-11-08
• BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3240572A1

  公开（公告）日：2017-11-08
• [EN] TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS<br/>[FR] COMPOSÉS ALCOOL TERTIAIRE IMIDAZOPYRAZINE INHIBITEURS DE LA BTK
  申请人：MERCK SHARP & DOHME

  公开号：WO2016109222A1

  公开（公告）日：2016-07-07

  The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, Formula I or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.